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ABSTRACT 
In the pharmaceutical R&D the evaluation procedures play a key role in developing a potent graded product focusing on the various tech nical 
advancements it’s easy to overcome hazards. Emphasis is placed on the product’s development to reach specifications of USFDA,  US 
Pharmacopeia, National Formulary for achieving standards that provide insight on evaluation techniques of drug formulation. Adoption of 
guidance’s and guidelines cited will strive for achieving good laboratory practice(GLP) good clinical practice(GCP) and good manufacturing 
practice(cGMP).Embracing  statistical approach provides accuracy and reliability of results. 
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INTRODUCTION:  
Good statistics practice (GSP)is the set of principles or the 
standard operating procedures to validate the (or) conduct, 
analysis, evaluation of the pharmaceutical product at various 
stages of it’s research and development (R&D). 
These procedures or principles help out to minimize the bias  
and variability that occur before during or after the product 
development the concept of GSP has raised forward by 
relating or following the standards  and specifications raised 
by the USFDA and formularies and other regulatory bodies, 
for example the us regulatory requirements for drug 
research and development aides by the pharmacopeia and 
national formulary which includes set of procedures 
,sampling techniques and  acceptance criteria for the 
development of a pharmaceutical product. 
The guidelines and guidance will help out for achieving the 
standards of good manufacturing practices(GMP)good 
clinical practice(GCP) and current good manufacturing 
practice(cGMP),Recently the ICH have outlined the concept 
of GSP on statistical principles for clinical trials that not only 
provide accuracy & reliability but also validity and integrity 
of the studies. 
ROLE OF STATISTICS IN DRUG DEVELOPMENT: 
During the process of drug research and development (R&D) 
statistics are necessarily applied at various stages to meet 
regulatory requirements for the effectiveness, safety, 
identity, purity, of the drug product under investigation. 
These includes a hectic process that involves screening of 
wide number of compounds in order to differentiate & 
identify the various potencies of the compound required for 
the formulation of the drug product. 
As the process involves following the guidelines aided by 
FDA and IND regarding the chemistry manufacturing and 
control (CMC) of the drug product that provides the identity 
of the drug and differentiate it in terms of efficacy kinetics 
and pharmacological aspects of drug in the intrinsic 
environment. 
The drug statistics are applied in order to validate a 
developed analytical method or to determine the expiration 
date through stability studies to analyze toxicity through 
stability studies and analyze toxicity through animal studies 
before gets marketed, There is a need to analyze it’s 
properties according to the guidelines of regulatory bodies 
involving various statistical techniques cited in technical 
section of statistics in NDA. After the approval by the FDA it 
requires that drug product be tested for it’s identity, 
strength  quality and purity before it can be released into the 
market so there is a need to analyze and provide quality 
assurance of the final product. 
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BIAS AND VARIABILITY:  
For the approval of a drug regulatory agencies usually 
require results of studies conducted at various stages of drug 
research and development (R&D) and provide a fair 
assessment for treatment of different ailments which 
together relate accuracy and reliability referred as closeness 
and degree of results to true value. 
Any deviation of true value will lead to bias that occur due to 
false statistical procedures ,The reliability of a study is an 
assessment of precision that measure degree of closeness to 
true value the higher the precision the more likely the 
results are reproducible. 
CONFOUNDING & INTERACTION: 
During drug research and development(R&D) there exists a 
different critical ailments that have impact on evaluation of 
treatment, These variations when not identified and 
controlled will  deploy the potency of the drug, Therefore 
statistical interaction is employed to investigate whether the 
contribution of each factor when considered alone in 
practice show  possible confounding results and interactions 
to be identified and controlled at different stages in order to 
ensure the constant effectiveness of the product. 
TYPE-I ERROR: 
Error is defined as a process or mistake that occurs during a 
process unknowingly they are divided into two types, i’e 
type- I&II. 
Type-I errors are serious and should take a limit the 
probability of committing this kind of error to a acceptable 
level, The acceptable level of type-I error is referred as 
significance level. A statistically significant result suggests 
that the null hypothesis be rejected in favour of alternative 
hypothesis, The probability of observing  a type -I error is 
usually referred as P-value of test on the other hand 
probability of committing type-II error subtracted from 
type-I is called power of test. 
RANDOMIZATION: 
The interference on a parameter of interest of a population 
under study is usually derived under probability structure of 
parameter. Sampling is one of the methods where 
probability structure depends upon randomization which 
gives a negative impact on validity of probability structure, 
Therefore appropriate randomization methods under a valid 
model should be employed to ensure validity accuracy, 
reliability of statistical inference. 
Sample size determination:  
Sample size determination generally involves calculation of 
sample size for desired statistical properties such as 
precision, sample size justification etc. The objective is to 
determine whether the drug is effective an safe sample size 
can be determined/justified based on some criteria of type-I 
error or type-II error. In order to obtain the accurate result 
there need to be following certain criteria they are:- 
 Study objective should be clearly stated 
 A valid design with appropriate statistical tests should 
be used  
 Sample size should be determined based on test of 
interest. 
 
 
Statistical difference &scientific difference:  
It is defined as a difference that is unlikely to occur by 
chance alone, while a scientific difference is a tolerance that 
is considered to be scientific importance it is also called 
statistical significance. 
One sided v/s Two sided test: 
For the evaluation of drug product the null hypothesis of 
interest is often no difference the alternative hypothesis is 
usually there is a difference this type of test is called two 
sides test. Sometimes there exists difference against the 
alternative hypothesis that the drug is superior this the 
statistical test for this setting is called one side test. The 
pharmaceutical industry either uses a one sides or two sided 
test which has been challenged by several companies on 
drug efficacy & study implementation (DESI) drugs. 
European statistics code of good practice: 
In February-2005 the statistical program committee has 
adopted the European statistics code of good practice and 
undertook to observe the fifteen principles established this 
code was embraced by (INEI). 
1) Professional Independence 
2) Mandate for data collection 
3) Adequacy & resources 
4) Quality commitment 
5) Statistical confidentially 
6) Impartiality & objectivity 
7)Sound methodology 
8) Appropriate statistical procedures 
9) Nom excessive burden on respondents 
10Cost effectiveness 
11Relevance 
12Accuracy & reliability 
13Timeliness & punctuality 
14) Coherence & compatibility 
15) Accessibility & clarity 
Implementation of GSP: 
The consideration of good statistical practice during the 
product research and development (R&D) will effect the 
various ailments that define the properties to consolidate 
the characteristics according to various regulatory bodies,In 
the process  of drug development there need to follow 
guidelines for effective and potent drug to be formulated 
these standards will describe the drug in all aspects that 
ensure safety of pharmaceutical product. 
Communication and flexibility are important for the success 
of GSP.Improper/Inefficient communication between 
statisticians and pharmaceutical scientists or regulatory 
bodies will effect product development and failure in the 
statistical methods .The regulatory requirements of the drug 
development and approval process vary from drug to 
another drug therefore statistical coordinated advanced 
education should be provided for the efficacy of the 
pharmaceutical product. The enhancement of various 
techniques in different stages of product development will 
ensure a full-fledged potent pharmaceutical product. A panel 
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discussion of various different disciplines to be hold 
together to evaluate the standards and the statistical 
principles for implementation of GSP. 
CONCLUSION: 
There exists various aspects of properties standards & 
characteristics to be considered  before marketing the 
pharmaceutical product which are maintained accordingly 
by guidance of formularies, regulatory bodies, standard 
operating procedures, GLP, GCP, CGMP, GRP, etc.  The 
pharmaceutical product being manufactured  should be 
formulated with utmost concern following all the regulatory  
standards principles to enhance the drug properties in terms 
of potency and efficacy this can only be achieved when there 
exists a healthy relation between the industry with 
regulatory bodies, statisticians, scientists. 
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